KRAS and neoplasm: For example, MAPK and cyclin-dependent kinase 4/6 inhibitors act in concert to suppress the proliferation of KRAS-mutant lung cancer cells by triggering the accumulation of NK cells within the tumor and promoting NK cell-dependent tumor cell killing [75].